FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080644701> ?p ?o ?g. }

• W2080644701 endingPage "410" @default.
• W2080644701 startingPage "406" @default.
• W2080644701 abstract "In our previous study of patients with early-phase severe traumatic brain injury (TBI), the anti-inflammatory interleukin (IL)-10 concentration was lower in cerebrospinal fluid (CSF) than in serum, whereas proinflammatory IL-1β and tumor necrosis factor (TNF)-α concentrations were higher in CSF than in serum. To clarify the influence of additional injury on this disproportion between proinflammatory and anti-inflammatory mediators, we compared their CSF and serum concentrations in patients with severe TBI with and without additional injury. All 35 study patients (18 with and 17 without additional injury) had a Glasgow Coma Scale score of 8 or less upon admission. With the exception of additional injury, clinical characteristics did not differ significantly between groups. CSF and serum concentrations of two proinflammatory mediators (IL-1β and TNF-α,) and three anti-inflammatory mediators (IL-1 receptor antagonist [IL-1ra], soluble TNF receptor-I [sTNFr-I], and IL-10) were measured and compared at 6 h after injury. CSF concentrations of proinflammatory mediators were much higher than the corresponding serum concentrations in both patient groups (P < 0.001). In contrast, serum concentrations of anti-inflammatory mediators were much higher than the paired CSF concentrations in patients with additional injury (P < 0.001), but serum concentrations were lower than or equal to the corresponding CSF concentrations in patients without additional injury. CSF concentrations of IL-1β, IL-1ra, sTNFr-I, and IL-10 were significantly higher (P < 0.01 for all) in patients with high intracranial pressure (ICP; n = 11) than in patients with low ICP (n = 24), and were also significantly higher (P < 0.05 for all) in patients with an unfavorable outcome (n = 14) than in patients with a favorable outcome (n = 21). These findings indicate that increased serum concentrations of anti-inflammatory mediators after severe TBI are mainly due to additional extracranial injury. We conclude that anti-inflammatory mediators in CSF may be useful indicators of the severity of brain damage in terms of ICP as well as overall prognosis of patients with severe TBI." @default.
• W2080644701 created "2016-06-24" @default.
• W2080644701 creator A5000425806 @default.
• W2080644701 creator A5009153404 @default.
• W2080644701 creator A5009380252 @default.
• W2080644701 creator A5013457309 @default.
• W2080644701 creator A5037518615 @default.
• W2080644701 creator A5039057109 @default.
• W2080644701 creator A5042321088 @default.
• W2080644701 creator A5047839525 @default.
• W2080644701 creator A5059174512 @default.
• W2080644701 creator A5070350057 @default.
• W2080644701 creator A5077042616 @default.
• W2080644701 creator A5088019448 @default.
• W2080644701 date "2005-05-01" @default.
• W2080644701 modified "2023-10-15" @default.
• W2080644701 title "CEREBROSPINAL FLUID CONCENTRATIONS OF ANTI-INFLAMMATORY MEDIATORS IN EARLY-PHASE SEVERE TRAUMATIC BRAIN INJURY" @default.
• W2080644701 cites W1556136861 @default.
• W2080644701 cites W1603121691 @default.
• W2080644701 cites W1874700596 @default.
• W2080644701 cites W1978438594 @default.
• W2080644701 cites W1990942988 @default.
• W2080644701 cites W1999377197 @default.
• W2080644701 cites W1999701898 @default.
• W2080644701 cites W2004626340 @default.
• W2080644701 cites W2012338377 @default.
• W2080644701 cites W2013700204 @default.
• W2080644701 cites W2014473727 @default.
• W2080644701 cites W2044692802 @default.
• W2080644701 cites W2057290284 @default.
• W2080644701 cites W2058932445 @default.
• W2080644701 cites W2067792052 @default.
• W2080644701 cites W2074229539 @default.
• W2080644701 cites W2087599304 @default.
• W2080644701 cites W2091317588 @default.
• W2080644701 cites W4293108385 @default.
• W2080644701 doi "https://doi.org/10.1097/01.shk.0000161385.62758.24" @default.
• W2080644701 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15834305" @default.
• W2080644701 hasPublicationYear "2005" @default.
• W2080644701 type Work @default.
• W2080644701 sameAs 2080644701 @default.
• W2080644701 citedByCount "128" @default.
• W2080644701 countsByYear W20806447012012 @default.
• W2080644701 countsByYear W20806447012013 @default.
• W2080644701 countsByYear W20806447012014 @default.
• W2080644701 countsByYear W20806447012015 @default.
• W2080644701 countsByYear W20806447012016 @default.
• W2080644701 countsByYear W20806447012017 @default.
• W2080644701 countsByYear W20806447012018 @default.
• W2080644701 countsByYear W20806447012019 @default.
• W2080644701 countsByYear W20806447012020 @default.
• W2080644701 countsByYear W20806447012021 @default.
• W2080644701 countsByYear W20806447012022 @default.
• W2080644701 countsByYear W20806447012023 @default.
• W2080644701 crossrefType "journal-article" @default.
• W2080644701 hasAuthorship W2080644701A5000425806 @default.
• W2080644701 hasAuthorship W2080644701A5009153404 @default.
• W2080644701 hasAuthorship W2080644701A5009380252 @default.
• W2080644701 hasAuthorship W2080644701A5013457309 @default.
• W2080644701 hasAuthorship W2080644701A5037518615 @default.
• W2080644701 hasAuthorship W2080644701A5039057109 @default.
• W2080644701 hasAuthorship W2080644701A5042321088 @default.
• W2080644701 hasAuthorship W2080644701A5047839525 @default.
• W2080644701 hasAuthorship W2080644701A5059174512 @default.
• W2080644701 hasAuthorship W2080644701A5070350057 @default.
• W2080644701 hasAuthorship W2080644701A5077042616 @default.
• W2080644701 hasAuthorship W2080644701A5088019448 @default.
• W2080644701 hasBestOaLocation W20806447011 @default.
• W2080644701 hasConcept C118552586 @default.
• W2080644701 hasConcept C126322002 @default.
• W2080644701 hasConcept C134018914 @default.
• W2080644701 hasConcept C164027704 @default.
• W2080644701 hasConcept C17624336 @default.
• W2080644701 hasConcept C17991360 @default.
• W2080644701 hasConcept C2776914184 @default.
• W2080644701 hasConcept C2778690821 @default.
• W2080644701 hasConcept C2779651940 @default.
• W2080644701 hasConcept C2781017439 @default.
• W2080644701 hasConcept C42219234 @default.
• W2080644701 hasConcept C71924100 @default.
• W2080644701 hasConcept C74172505 @default.
• W2080644701 hasConcept C90924648 @default.
• W2080644701 hasConceptScore W2080644701C118552586 @default.
• W2080644701 hasConceptScore W2080644701C126322002 @default.
• W2080644701 hasConceptScore W2080644701C134018914 @default.
• W2080644701 hasConceptScore W2080644701C164027704 @default.
• W2080644701 hasConceptScore W2080644701C17624336 @default.
• W2080644701 hasConceptScore W2080644701C17991360 @default.
• W2080644701 hasConceptScore W2080644701C2776914184 @default.
• W2080644701 hasConceptScore W2080644701C2778690821 @default.
• W2080644701 hasConceptScore W2080644701C2779651940 @default.
• W2080644701 hasConceptScore W2080644701C2781017439 @default.
• W2080644701 hasConceptScore W2080644701C42219234 @default.
• W2080644701 hasConceptScore W2080644701C71924100 @default.
• W2080644701 hasConceptScore W2080644701C74172505 @default.
• W2080644701 hasConceptScore W2080644701C90924648 @default.
• W2080644701 hasIssue "5" @default.
• W2080644701 hasLocation W20806447011 @default.

• next